	Screening	Therapy																
Cycle No.		1				,	2	3 4			6	<b>7</b> <sup>a</sup>	8	9	10	n <sup>b</sup>	End of	Follow
Duration		28			28		28	28	28	28	28	28	28	28	28	Study	Up	
Relative day within cycle	≤ 28	1	<b>8</b> <sup>c</sup>	15	22	1	15	<b>1</b> <sup>d</sup>	-	1	-	1	-	-	1	1	Visit	Visit
<b>Baseline Procedures</b>																		
Informed Consent	X																	
Inclusion/Exclusion	X																	
Demography, relevant medical history, current medical conditions including GIST specific history <sup>e</sup>	X																	
Height (baseline only) and weight	X																	
<b>Routine Examinations</b>																		
Prior/Concomitant Medications, significant non-drug therapies Physical Examination	X	X	X	X	X	X	X	X		X		X			X	X		
Vitals	X	X	X	X	X	X	X	X		X		X			X	X		
AEs and SAEs	Λ	X	X	X	X	X	X	X		X		X			X	X	X	X
Laboratory Tests		Λ	Λ	Λ	Λ	Λ	Λ	Λ		Λ		Λ			Λ	Λ	Λ	Λ
Hematology	X	X	X	X	X	X	X	X		X		X			X			
Serum Chemistries	X	X	X	X	X	X	X	X		X		X			X			
Pregnancy Test <sup>f</sup>	X	X															X	
Peripheral blood for PK analysis		X			X <sup>g</sup>													

	Screening	Therapy																
Cycle No.		1				2	3	4	5	6	7	8	9	10	n	End of	Follow	
Duration		28			28		28	28	28	28	28	28	28	28	28	Study	Up	
Relative day within	≤ 28	1	8	15	22	1	15	1	-	1	-	1	-	-	1	1	Visit	Visit
cycle																		
<b>Tumor Assessment</b>																		
CT or MRI of abdomen	X							X		X		X			X	X		X
and pelvis <sup>h</sup>	Λ							Λ		Λ		Λ			Λ	1		Λ
CT of chest <sup>i</sup>	X																	X
FDG-PET imaging	X					$X^{j}$												
Fresh tumor biopsy for																		
mutational analysis and																	X	
exploratory biomarkers																		

<sup>a</sup> After Cycle 7, patients will be seen every 3 cycles until the end of study

<sup>&</sup>lt;sup>b</sup> Patients will take CP-868,596 continuously until they fulfill one of the criteria for study discontinuation

<sup>&</sup>lt;sup>c</sup> Visits during the first 2 cycles: ± 3 days

<sup>&</sup>lt;sup>d</sup> Visits from the 3rd cycle to the end of study:  $\pm$  5 days

<sup>&</sup>lt;sup>e</sup> History should include site of primary tumor, metastatic sites, GIST histology, time of relapses, PDGFR mutation status, tumor Kit expression

<sup>&</sup>lt;sup>f</sup> Only for WOCBP; Includes a serum pregnancy test at screening, urine pregnancy test on Day 1 of Cycle 1, and a serum pregnancy test at EOS visit

<sup>&</sup>lt;sup>g</sup> The second sample for PK may be drawn anytime between days 15 and 28 of cycle 1

<sup>&</sup>lt;sup>h</sup> After cycle 7, CT scans of the abdomen and pelvis will be done quarterly

<sup>&</sup>lt;sup>1</sup> Chest CT will be done at baseline and thereafter at physician's discretion

<sup>&</sup>lt;sup>1</sup> FDG-PET imaging can be done anytime between day 1 of cycle 2 and day 1 of cycle 3